Treatment of venous thromboembolism with dabigatran

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 5, 2012, Pages 410-415

  Schulman, Sam ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

acute coronary syndrome; bleeding; thrombin inhibitor; venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN; FONDAPARINUX; HEPARIN; IDRAPARINUX; PLACEBO; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FECES LEVEL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MORTALITY; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; RECURRENCE; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84864881869     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835466eb     Document Type: Review

References (22)

1. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-2352.
2. Schulman S, Eriksson H, Goldhaber S, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism [abstract]. J Thromb Haemost 2011; 9 (Suppl 2):731-732.
3. Schulman S, Kakkar AK, Schellong S, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RECOVER II). In: Proceedings of American Society of Hematology Conference, San Diego; 2011. Abstract 205.
4. chulman S, Baanstra D, Eriksson H, et al. Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism [abstract]. J Thromb Haemost 2011; 9:22.
5. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499-2510.
6. Buller HR, Prins MH, Lensing AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-1297.
7. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3:692-694. (Pubitemid 41647882)
8. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
9. ikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
10. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386-399. (Pubitemid 351185753)
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
12. Büller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357:1094-1104. (Pubitemid 47443214)
13. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172:397-402.
14. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RELY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125:669-676.
15. European Medicines Agency update on safety of Pradaxa. European Medicines Agency, EMA/CHMP/903767/2011. www.ema.europa.eu/docs/en-GB/document-library/ Press-release/2011/11/WC500117818.pdf. [Accessed 11 March, 2012]
16. FDA Drug Safety Communication: Safety review of postmarket reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). U.S. Food and Drug Administration, 2011. www.fda.gov/Drugs/ DrugSafety/ucm282724.htm. [Accessed 11 March, 2012]
17. Monreal M, Falga C, Valle R, et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119:1073-1079. (Pubitemid 44834366)
18. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124:1573-1579.
19. van Ryn J. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran [abstract]. J Am Coll Cardiol 2011; 57:E1130.
20. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366:864-866.
21. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011; 365:2039-2040.
22. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.